Intellia Therapeutics Lonvo-z Phase 3

Summary Intellia reported additional positive Phase 3 data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, reinforcing earlier primary endpoint success and strengthening the regulatory profile of one of the most advanced in vivo CRISPR programs globally. What Happened New Phase 3 results demonstrated statistically and…